Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme

Giuseppe Luigi Banna, Daniela Bettio, Marta Scorsetti, Pierina Navarria, Matteo Simonelli, Riccardo Rodriguez Baena, Enrico Aimar, Paolo Gaetani, PierGiuseppe Colombo, Felice Rognone, Armando Santoro

Research output: Contribution to journalArticle

Abstract

Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.

Original languageEnglish
Pages (from-to)323-325
Number of pages3
JournalJournal of Neuro-Oncology
Volume81
Issue number3
DOIs
Publication statusPublished - Feb 2007

Fingerprint

temozolomide
Glioblastoma
Glioma
Radiotherapy
Disease Progression
Discitis
Fluorescence In Situ Hybridization
Neoplasms
Anti-Bacterial Agents

Keywords

  • Adjuvant therapy
  • Concomitant therapy
  • High-grade glioma
  • Malignant glioma
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

@article{4f79f81727c3418ebfd443fdbd50c7d8,
title = "Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme",
abstract = "Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.",
keywords = "Adjuvant therapy, Concomitant therapy, High-grade glioma, Malignant glioma, Radiotherapy, Temozolomide",
author = "Banna, {Giuseppe Luigi} and Daniela Bettio and Marta Scorsetti and Pierina Navarria and Matteo Simonelli and {Rodriguez Baena}, Riccardo and Enrico Aimar and Paolo Gaetani and PierGiuseppe Colombo and Felice Rognone and Armando Santoro",
year = "2007",
month = "2",
doi = "10.1007/s11060-006-9234-x",
language = "English",
volume = "81",
pages = "323--325",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme

AU - Banna, Giuseppe Luigi

AU - Bettio, Daniela

AU - Scorsetti, Marta

AU - Navarria, Pierina

AU - Simonelli, Matteo

AU - Rodriguez Baena, Riccardo

AU - Aimar, Enrico

AU - Gaetani, Paolo

AU - Colombo, PierGiuseppe

AU - Rognone, Felice

AU - Santoro, Armando

PY - 2007/2

Y1 - 2007/2

N2 - Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.

AB - Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.

KW - Adjuvant therapy

KW - Concomitant therapy

KW - High-grade glioma

KW - Malignant glioma

KW - Radiotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=33846502804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846502804&partnerID=8YFLogxK

U2 - 10.1007/s11060-006-9234-x

DO - 10.1007/s11060-006-9234-x

M3 - Article

C2 - 17031557

AN - SCOPUS:33846502804

VL - 81

SP - 323

EP - 325

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -